Comprehensive In Vitro Proarrhythmia Assay (CIPA)
Cambridge Bioscience, through B’SYS, offers access to a fully defined, comprehensive in vitro proarrhythmia assay (CIPA) package addressing the CIPA Initiative which will replace existing ICH S7a/b guidelines.
Combining cardiac ion channel panel screening (using pharmacological profiling through classical patch clamp electrophysiology) and the screening of validated beating iPSC human cardiomyocytes (on the multiple-electrode array (MEA) against reference compounds with known clinical outcomes), this service provides a more comprehensive screening than measuring hERG-induced QT prolongation alone.
Benefits Of Using This CIPA Package
• High quality data
• Comprehensive cardiac safety screen
• Multiple ion channel effects screen included - testing for hERG, Cav1.2 & Nav1.5
• Low to high throughput formats available
• Superior to hERG model in predicting Torsade de Pointes
• Fast 2-4 week timeline
Contact Our Specialists
To discuss a CIPA package project, please contact our B'SYS specialist by Clicking Here